- Home
- BTMD vs FENC Comparison
BTMD vs FENC Comparison
Compare BTMD & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- FENC
- Stock Information
- Founded
- BTMD 2012
- FENC 1996
- Country
- BTMD United States
- FENC United States
- Employees
- BTMD N/A
- FENC N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- FENC Health Care
- Exchange
- BTMD Nasdaq
- FENC Nasdaq
- Market Cap
- BTMD 136.0M
- FENC 156.9M
- IPO Year
- BTMD N/A
- FENC 2001
- Fundamental
- Price
- BTMD $3.07
- FENC $6.13
- Analyst Decision
- BTMD Strong Buy
- FENC Strong Buy
- Analyst Count
- BTMD 1
- FENC 2
- Target Price
- BTMD $8.00
- FENC $14.00
- AVG Volume (30 Days)
- BTMD 220.4K
- FENC 58.2K
- Earning Date
- BTMD 03-12-2025
- FENC 03-10-2025
- Dividend Yield
- BTMD N/A
- FENC N/A
- EPS Growth
- BTMD N/A
- FENC N/A
- EPS
- BTMD 0.09
- FENC N/A
- Revenue
- BTMD $197,191,000.00
- FENC $47,538,000.00
- Revenue This Year
- BTMD $17.51
- FENC $28.99
- Revenue Next Year
- BTMD $15.84
- FENC $63.21
- P/E Ratio
- BTMD $34.33
- FENC N/A
- Revenue Growth
- BTMD 6.38
- FENC 123.69
- 52 Week Low
- BTMD $3.04
- FENC $3.96
- 52 Week High
- BTMD $8.44
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- BTMD 22.01
- FENC 40.18
- Support Level
- BTMD $4.03
- FENC $5.75
- Resistance Level
- BTMD $4.23
- FENC $6.64
- Average True Range (ATR)
- BTMD 0.27
- FENC 0.35
- MACD
- BTMD -0.05
- FENC -0.09
- Stochastic Oscillator
- BTMD 1.62
- FENC 29.01
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.